Moderna, Inc. 8-K

What Happened
Moderna, Inc. announced on July 8, 2026 (8-K filed) that Michael McDonnell was appointed to its Board of Directors effective July 8, 2026. Mr. McDonnell, a finance executive with more than 35 years of public-company experience (most recently CFO of Biogen from Aug 2020–Feb 2025), was named a Class II director to serve until the 2029 annual meeting and was appointed to Moderna’s Audit Committee. Concurrently, director David Rubenstein left the Audit Committee and joined the Nominating and Corporate Governance Committee.

Key Details

• Appointment effective date: July 8, 2026. Term: Class II director through the 2029 annual meeting.
• Committee change: McDonnell added to the Audit Committee; David Rubenstein moved to the Nominating and Corporate Governance Committee.
• Compensation: McDonnell is eligible for Moderna’s non-employee director pay under the company’s policy (will receive an Initial Grant and a pro‑rata Annual Grant per the 2026 Proxy Statement).
• Other governance facts: He entered Moderna’s standard indemnification agreement; no family ties, related-party transactions, or special arrangements were reported.

Why It Matters
For investors, this is a governance and oversight update: Moderna added an experienced finance executive and former public‑company CFO to its board and Audit Committee, which is directly relevant to financial oversight and reporting. The filing shows routine director compensation under existing policy and no related-party issues, indicating a standard, governance-focused appointment rather than a material corporate transaction.